Ultimately, urinary S100B holds promise as an early, noninvasive biomarker of IH-related brain injury in preterm infants, and its incorporation into neonatal care may enable earlier detection, risk stratification, and targeted intervention to mitigate brain injury. Here, S100B is linked to isolated hemihyperplasia.